Mechanisms of Disease: temozolomide and glioblastoma—look to the future
- 10 June 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 5 (8) , 476-486
Abstract
Until recently, the standard of care for the treatment of glioblastoma involved surgical resection followed by radiation therapy with or without nitrosourea-based chemotherapy. In 2005, a large trial established adjuvant temozolomide chemotherapy and radiotherapy as a new standard therapy. This Review summarizes new developments in the treatment of glioblastoma and speculates on possible future treatment strategies for managing this aggressive cancer. Glioblastoma is both the most common and most aggressive primary brain tumor. Until recently, the standard of care involved maximal safe surgical resection followed by radiation therapy with or without nitrosourea-based chemotherapy. In 2005, the results of a large clinical trial examining the role of adjuvant chemotherapy in management of newly diagnosed glioblastoma were published. This study created a new standard of adjuvant treatment, using concurrent and sequential temozolomide in the initial therapy of glioblastoma. A companion tumor biology study identified the prognostic role of O6-methylguanine-DNA methyltransferase (MGMT) status in patients with newly diagnosed glioblastoma. Several preliminary studies have been initiated to address the issue of resistance and suppression of MGMT activity, and have used alternative temozolomide dosing schedules and O6-guanine mimetic agents as substrates for MGMT. In addition, recent studies have attempted to define mechanisms responsible for the apparent synergy between temozolomide and radiotherapy. Lastly, an increased understanding of the molecular biology of glioblastoma has provided new leads for the adjuvant treatment of this disease. This Review summarizes new developments in treatment of glioblastoma and speculates on possible future treatment strategies for managing this aggressive cancer.Keywords
This publication has 61 references indexed in Scilit:
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Synergistic antiglioma activity of radiotherapy and enzastaurinAnnals of Neurology, 2007
- The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1Neuro-Oncology, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumoursEuropean Journal of Cancer, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Pharmacological Rescue of Mutant p53 Conformation and FunctionScience, 1999
- In vitro evaluation of temozolomide combined with X-irradiationAnti-Cancer Drugs, 1997